Evidence map›Paper›PMID 28426793›Full record

SynthesisPloS one2017

Prevalence of cardiovascular medication on secondary prevention after myocardial infarction in China between 1995-2015: A systematic review and meta-analysis.

Min Zhao, Kerstin Klipstein-Grobusch, Xin Wang, Johannes B Reitsma, Dong Zhao, Diederick E Grobbee, Ian Graham, Ilonca Vaartjes

Abstract readHistorical ArticleMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Observational
  4. Article
  5. Article
  6. Dietary diversity indicesPublic health nutrition · 2023
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Polydatin protects H9c2 cells from hypoxia-induced injury via up-regulating long non-coding RNA DGCR5.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Min ZhaoJulius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-7442-1655
Kerstin Klipstein-GrobuschJulius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Utrecht, The Netherlands.
Xin WangJulius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Utrecht, The Netherlands.
Johannes B ReitsmaJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Utrecht, The Netherlands.
Dong ZhaoCapital Medical University Beijing Anzhen Hospital, Beijing, Beijing, China.
Diederick E GrobbeeJulius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Utrecht, The Netherlands.
Ian GrahamTrinity College Dublin, Dublin, Dublin, Ireland.
Ilonca VaartjesJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Utrecht, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMyocardial Infarction (MI) has become a major cause of morbidity and mortality in China, but little is known about the prevalence of guideline-recommended cardiovascular medications after MI events over the last two decades. This systematic review and meta-analysis aims to summarize cardiovascular medication use between 1995-2015 and to assess factors in associated with the trends in cardiovascular medications.

methodA systematic search was conducted in four databases (Pubmed, Embase, CENTRAL, and CNKI) to obtain observational studies published between 1995 and 2015, reporting on the use of cardiovascular medications in China. Risk of bias of individual studies was appraised and selected studies were pooled for estimated prevalence of cardiovascular medication. Prevalence of cardiovascular medication use for 1995 and 2015 was estimated by random effects meta-regression model.

resultsFrom 13,940 identified publications, 35 studies, comprising 28,000 patients, were included. The pooled prevalence for aspirin, beta-blockers, statins, ACE-Inhibitors, ACE-Inhibitor/ARBs and nitrates was 92% [95% confidence interval (CI): 0.89-0.95], 63% (95% CI: 0.57-0.69), 72% (95% CI: 0.60-0.82), 49% (95% CI: 0.41-0.57), 59% (95% CI: 0.48-0.69) and 79% (95% CI: 0.74-0.91), respectively. A significant increase in beta-blocker and statin use and a decrease of nitrate use was observed over time. The estimated prevalence of beta-blockers, statins, and nitrates was 78%, 91.1%, and 59.3% in 2015, compared to 32%, 17% and 96% in 1995, respectively.

conclusionCardiovascular medication use after MI is far from optimal in Chinese patients, even though the prevalence of use increased over the period 1995-2015. With a rapidly increasing number of MI patients in China, a comprehensive strategy on secondary prevention is warranted. SYSTEMATIC REVIEW REGISTRATION: PROSPERO (CRD42015025246).

Indexed as

Cardiovascular AgentsChinaHistory, 20th CenturyHistory, 21st CenturyHumansMyocardial InfarctionPrevalenceSecondary PreventionCardiovascular Agents

Identifiers

PMID28426793
PMCPMC5398555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.